Project Grant HT94252310935
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$856K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,683,194.00 to Brigham & Women's Hospital Inc. over a period from Aug 1, 2025 to Jul 31, 2028. The funding supports research to investigate the role of the glycome in identifying biomarkers and understanding the molecular pathogenesis of tuberous sclerosis complex (TSC). Brigham & Women's Hospital, a prominent academic medical center and research...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) in the amount of $793,572.00 is effective August 15, 2024 and runs through August 14, 2027. The award has been transferred from the General Hospital Corporation to Brigham and Women's Hospital Inc. in Boston, MA. The grant will fund a research project titled "A NOVEL TRANSLATIONAL MECHANISM UNDERLYING TSC PATHOPHYSIOLOGY". Brigham and Women's Hospital, a prominent...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...
The federal Project Grant award of $266,368 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Brigham & Women's Hospital Inc. supports research on "MECHANISMS OF IMMUNE SUPPRESSION IN TSC". The research aims to investigate critical aspects of immune function related to the genetic disorder tuberous sclerosis complex (TSC). The award has a performance period from July 15, 2025 to July 14, 2027 and is part of the Defense Health Agency's...
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
This $172,374 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Brigham & Women's Hospital, Inc. (a subsidiary of Partners Healthcare System) to investigate the role of fatty acid metabolism in chromophobe renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing understanding of this type of kidney cancer. The...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $772,626 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM). The research, which commenced on August 1, 2025 and is scheduled for completion by July 31, 2028, aims to transform healthcare for military service...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
This $178,999 federal Project Grant, awarded on May 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Brigham & Women's Hospital Inc. to target TFE3 fusion proteins using PROTAC (Proteolysis Targeting Chimera) in translocation renal cell carcinoma (TRCC). The research aims to transform healthcare for military service members, veterans, and the broader public by developing innovative medical solutions. Brigham...